Trump Drug Pricing & PBMs: Will Policies End Them?
TrumpS potential impact on drug pricing is under scrutiny as pharmaceutical companies explore direct-to-consumer sales. This shift in the healthcare landscape, debated on the Debunked Podcast and featuring Arundhati Parmar, could drastically alter pricing models and the role of Pharmacy benefit Managers (PBMs). Arkansas has already taken a stand by banning PBMs from owning pharmacies, with other states considering similar moves. Together, UnitedHealth Group‘s CEO was replaced due to financial concerns, adding another layer of complexity. At News Directory 3, we follow the latest developments closely. Discover what’s next in this evolving sector.
Pharma’s Direct-to-Consumer Role: Pricing and UnitedHealth’s CEO Shift
Updated June 9, 2025
A recent discussion on the Debunked Podcast, featuring MedCity news Editor-in-Chief Arundhati Parmar and Health Innovation Pitch Managing Partner Samir Batra, explored the potential impact of pharmaceutical companies selling directly to consumers. The conversation centered on pricing models and which companies are already adopting this direct-to-consumer strategy.
The debate around the role of direct-to-consumer (DTC) sales comes as states like Arkansas, Walmart’s home, are taking action. Arkansas has banned Pharmacy Benefit Managers (PBMs) from owning or operating retail pharmacies, a move other states are considering.
Batra said he appreciates what the Trump administration is trying to do. “In theory this makes sense,” Batra observed. “but if we eliminate the middlemen, the brokers, the fat disappears … and pharma gets to deal directly with the payers.”
Simultaneously occurring, UnitedHealth Group replaced CEO Andrew Witty with Chairman and former CEO Stephen Hemsley after disappointing quarterly earnings and a bleak 2025 outlook. This leadership change has fueled discussions about the payer’s Medicare Advantage challenges.
Adding to unitedhealth’s woes, a report by The Guardian alleged that UnitedHealthcare incentivized nursing homes to avoid transferring patients to hospitals to cut costs.
What’s next
the pharmaceutical industry and healthcare payers face continued scrutiny as they navigate pricing pressures and adapt to evolving market dynamics. Further developments are expected in state regulations regarding PBMs and the ongoing debate surrounding direct-to-consumer pharmaceutical sales.